Baxalta Incorporated v. Genentech, Inc., No. 22-1461 (Fed. Cir. Sept. 20, 2023)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Baxalta Inc. and Baxalta GmbH (collectively, Baxalta) appeal the United States District Court for the District of Delaware’s grant of summary judgment that claims 1 –4, 19, and 20 of U.S. Patent No. 7,033,590 are invalid for lack of enablement. For the following reasons, we affirm. B ACKGROUND A Blood clots are formed through a series of enzymatic activations known as the coagulation cascade. ’590 patent at 1:6–10.